{"title":"同种异体造血干细胞移植患者的无血疗法","authors":"Phyllis McKiernan, Eliana Baker, Melissa Baker","doi":"10.1188/24.CJON.463-468","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Allogeneic hematopoietic stem cell transplantation (alloHSCT) poses challenges for patients who decline blood products because of religious beliefs or other reasons. Despite potential curative prospects, many institutions refrain from offering alloHSCT to patients who decline blood products because of safety concerns associated with cytopenias.</p><p><strong>Objectives: </strong>This review focuses on one institution's experience of conducting alloHSCT without blood components, emphasizing preparation and supportive care.</p><p><strong>Methods: </strong>The approach of conducting alloHSCT without blood components, which involves ABO-compatible donor matching, nonmyeloablative regimens, and pretransplantation optimization of red blood cell production, is discussed.</p><p><strong>Findings: </strong>The clinical team can minimize transfusion needs by using erythropoiesis-stimulating agents, thrombopoietin agonists, and peri- and post-transplantation management strategies. These recommendations can ensure patient safety and successful outcomes with bloodless medicine.</p>","PeriodicalId":10350,"journal":{"name":"Clinical journal of oncology nursing","volume":null,"pages":null},"PeriodicalIF":1.3000,"publicationDate":"2024-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Bloodless Medicine in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.\",\"authors\":\"Phyllis McKiernan, Eliana Baker, Melissa Baker\",\"doi\":\"10.1188/24.CJON.463-468\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Allogeneic hematopoietic stem cell transplantation (alloHSCT) poses challenges for patients who decline blood products because of religious beliefs or other reasons. Despite potential curative prospects, many institutions refrain from offering alloHSCT to patients who decline blood products because of safety concerns associated with cytopenias.</p><p><strong>Objectives: </strong>This review focuses on one institution's experience of conducting alloHSCT without blood components, emphasizing preparation and supportive care.</p><p><strong>Methods: </strong>The approach of conducting alloHSCT without blood components, which involves ABO-compatible donor matching, nonmyeloablative regimens, and pretransplantation optimization of red blood cell production, is discussed.</p><p><strong>Findings: </strong>The clinical team can minimize transfusion needs by using erythropoiesis-stimulating agents, thrombopoietin agonists, and peri- and post-transplantation management strategies. These recommendations can ensure patient safety and successful outcomes with bloodless medicine.</p>\",\"PeriodicalId\":10350,\"journal\":{\"name\":\"Clinical journal of oncology nursing\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.3000,\"publicationDate\":\"2024-09-17\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical journal of oncology nursing\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1188/24.CJON.463-468\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"NURSING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical journal of oncology nursing","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1188/24.CJON.463-468","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"NURSING","Score":null,"Total":0}
Bloodless Medicine in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Background: Allogeneic hematopoietic stem cell transplantation (alloHSCT) poses challenges for patients who decline blood products because of religious beliefs or other reasons. Despite potential curative prospects, many institutions refrain from offering alloHSCT to patients who decline blood products because of safety concerns associated with cytopenias.
Objectives: This review focuses on one institution's experience of conducting alloHSCT without blood components, emphasizing preparation and supportive care.
Methods: The approach of conducting alloHSCT without blood components, which involves ABO-compatible donor matching, nonmyeloablative regimens, and pretransplantation optimization of red blood cell production, is discussed.
Findings: The clinical team can minimize transfusion needs by using erythropoiesis-stimulating agents, thrombopoietin agonists, and peri- and post-transplantation management strategies. These recommendations can ensure patient safety and successful outcomes with bloodless medicine.
期刊介绍：
The Clinical Journal of Oncology Nursing (CJON) is an official publication of the Oncology Nursing Society (ONS) and is directed to the practicing nurse specializing in the care of patients with an actual or potential diagnosis of cancer. CJON is a vehicle to promote the mission of ONS, which is to advance excellence in oncology nursing and quality cancer care. The CJON mission is twofold: to provide practical information necessary to care for patients and their families across the cancer continuum and to develop publication skills in oncology nurses.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
